Today’s cyclodextrin:
Oculis makes another great step to cross the final line with its dexamethasone #eyedrop formulated with its unique gamma-CD based #nanotechnology.

Once daily, OCS-01 meets primary endpoints demonstrating superior reduction in inflammation and pain vs. vehicle following cataract surgery.

OPTIMIZE’s results follow the positive and statistically significant top line results from stage 1 of the Phase 3 DIAMOND trial in Diabetic Macular Edema reported earlier this year, further highlighting the product’s potential for treating front- and back-of-the-eye diseases.

If approved, OCS-01 has the potential to become a new standard of care as the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.

Oculis | OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery